Simmons Bank Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Simmons Bank raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 60.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,224 shares of the medical research company’s stock after purchasing an additional 3,090 shares during the period. Simmons Bank’s holdings in Thermo Fisher Scientific were worth $5,087,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in TMO. Bancreek Capital Management LP lifted its stake in Thermo Fisher Scientific by 9.5% in the third quarter. Bancreek Capital Management LP now owns 15,733 shares of the medical research company’s stock worth $9,732,000 after acquiring an additional 1,359 shares during the period. Carrera Capital Advisors purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth about $1,466,000. Aptus Capital Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 18.9% during the 3rd quarter. Aptus Capital Advisors LLC now owns 37,765 shares of the medical research company’s stock valued at $23,360,000 after purchasing an additional 5,996 shares in the last quarter. Ashton Thomas Private Wealth LLC raised its stake in Thermo Fisher Scientific by 2.8% in the third quarter. Ashton Thomas Private Wealth LLC now owns 8,458 shares of the medical research company’s stock worth $5,232,000 after buying an additional 233 shares in the last quarter. Finally, Proactive Wealth Strategies LLC purchased a new stake in Thermo Fisher Scientific in the third quarter worth about $453,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Bank of America raised their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Royal Bank of Canada decreased their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Bernstein Bank upped their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the sale, the chief executive officer now owns 14,608 shares in the company, valued at $8,076,178.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Marc N. Casper sold 9,000 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the sale, the chief executive officer now directly owns 14,608 shares of the company’s stock, valued at $8,076,178.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,150 shares of company stock worth $20,651,865 in the last three months. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $540.63 on Wednesday. The stock has a 50-day simple moving average of $591.27 and a two-hundred day simple moving average of $583.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a 52-week low of $439.11 and a 52-week high of $627.88. The firm has a market capitalization of $206.79 billion, a PE ratio of 33.90, a P/E/G ratio of 3.61 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same quarter in the previous year, the company earned $5.69 EPS. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. Analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.